Incidence of Ocular Toxicity from Iron Chelating Agents at Siriraj Hospital
DOI:
https://doi.org/10.33192/Smj.2020.28Keywords:
Ocular toxicity, iron chelating agent, thalassemia, electroretinogramAbstract
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural and functional abnormalities, caused by iron chelating agents and detected by an electrophysiologic test at Siriraj Hospital.
Methods: A retrospective chart review was conducted of patients receiving multiple blood transfusions and iron chelation therapy who had an eye examination at Siriraj Hospital between January 1995 and December 2017.
Results: Ninety-seven charts were reviewed. The 88 patients included comprised 41 males and 47 females. Their ages ranged from 1 year 11 months to 47 years, with children predominant (mean: 8.13 years). Beta thalassemia HbE was the main diagnosis (87.5%). After receiving iron chelating agents, 3 patients had abnormal eye findings with suspected ocular toxicity. Two had retinal pigmentary changes, but only one of those two displayed a mildly decreased response in a scotopic electroretinogram. Although the third patient also showed a decreased electroretinogram response, there were no obvious retinal changes. All three received the iron chelating agents desferrioxamine, deferiprone, and/or deferasirox at different doses and for various durations.
Conclusion: Although some pigmentary retinopathy and decreased electroretinogram responses were found, leading to ocular toxicity being suspected, there was a very low incidence of ocular toxicity from the chelating agents. In addition, the dosages of the agents causing ocular toxicity, and the duration of that toxicity, were inconclusive. Moreover, a gold standard for identifying ocular toxicity caused by chelating agents was not able to be established. Consequently, the risks and benefits of employing eye screening coupled with an invasive procedure like an electrophysiologic test will need to be weighed, especially with pediatric patients.
References
2. Szwarcberg J, Mack G, Flament J. Ocular toxicity of deferoxamine: description and analysis of three observations. J Fr Ophtalmol 2002;25:609-14.
3. Marciani MG1, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, et al. Toxic effects of high–dose deferoxamine treatment in patients with iron overload: An electrophysiological study of cerebral and visual function. Haematologica 1991;76:131-4.
4. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, et al. Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions. N Engl J Med 1986;314:869-73.
5. Haimovici R, D'Amico DJ, Gragoudas ES, Sokol S; Deferoxamine Retinopathy Study Group. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002; 109:164-71.
6. Sen P, Bhende M, Ravi P, Roy R. Multifocal electroretinogram in desferrioxamine-related macular toxicity. Retin Cases Brief Rep 2010;4:224-8.
7. Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS. Desferrioxamine-related ocular toxicity: A case report. Indian J Ophthalmol 2012;60:315-7.
8. Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol 2010;58:125-30.
9. Pan Y, Keane PA, Sadun AA, Fawzi AA. Optical coherence tomography findings in deferasirox-related maculopathy. Retin Cases Brief Rep 2010;4:229-32.
10. Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina 2008;28:894-9.
11. Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr 1990;117(2 Pt 1):326-30.
Downloads
Published
How to Cite
Issue
Section
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.